Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 193

Results For "IMI"

3840 News Found

Lupin receives tentative approval from USFDA for Dolutegravir Tablets for oral suspension
Drug Approval | July 05, 2023

Lupin receives tentative approval from USFDA for Dolutegravir Tablets for oral suspension

Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD®) had estimated annual sales of USD 1 million in the U.S. (IQVIA MAT March 2023)


Zydus receives final approval from the USFDA for Oxcarbazepine Tablets
Drug Approval | July 05, 2023

Zydus receives final approval from the USFDA for Oxcarbazepine Tablets

The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)


Cipla bags sustainable companies rankings for 2022-23
News | July 05, 2023

Cipla bags sustainable companies rankings for 2022-23

Cipla has a robust governance model focused on sustainability


Venus Remedies gets marketing approvals for oncology medicine from 4 key markets
News | July 05, 2023

Venus Remedies gets marketing approvals for oncology medicine from 4 key markets

With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503


Lupin receives approval from FDA for Cyanocobalamin Nasal Spray
Drug Approval | July 04, 2023

Lupin receives approval from FDA for Cyanocobalamin Nasal Spray

Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)


Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules
News | July 04, 2023

Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules

The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models


Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24
Drug Approval | July 03, 2023

Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24

Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.


Granules India successfully completes Two US FDA Audits in a span of 2 weeks
Drug Approval | July 03, 2023

Granules India successfully completes Two US FDA Audits in a span of 2 weeks

The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.


Annovis’ Buntanetap in PD faces complex road ahead despite phase III progress, says GlobalData
News | July 03, 2023

Annovis’ Buntanetap in PD faces complex road ahead despite phase III progress, says GlobalData

The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023


Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program
News | June 30, 2023

Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program

Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully